SEATTLE & BALTIMORE--(BUSINESS WIRE)--June 5, 2006--Targeted Genetics Corporation (Nasdaq: TGEND - News) and the company’s academic collaborators reported multiple advances in the field of adeno-associated virus (AAV)-based product development in eight abstracts at the American Society of Gene Therapy 2006 Annual Meeting, which took place May 31 - June 4. The reported data provide insight into how to optimize the delivery, activation and long-term expression of AAV-based therapeutic products.
